How to Cite
1.
Fonseca Villanea C. Intrauterine devices in adolescents. Rev.méd.sinerg. [Internet]. 2017Apr.3 [cited 2024May20];2(4):3-7. Available from: https://www.revistamedicasinergia.com/index.php/rms/article/view/70
Abstract
The intrauterine device should be taken as the first line in the contraceptive plan for adolescent women.
Among the noncontraceptive effects are: the management of dysmenorrhea, endometriosis or dysfunctional uterine bleeding.
Its effectiveness does not change according to the age or parity of the user.There is no evidence that increases the risk of uterine perforation, pelvic inflammatory disease or difficulty at the time of insertion that serves as an excuse to exclude nulliparous adolescents from their use
Keywords
Device. contraceptive. intrauterine device. levonorgestrel.
References
1. The American College of Obstetrician and Gynecologist. (2012) Adolescents and Long-Acting Reversible Contraception: Implants and Intrauterine Devices. Committee on Adolescent Health Care Long-Acting Reversible Contraception Working Group. Number: 539.
2. The American College of Obstetrician and Gynecologist. (2011, reaffirmed 2015) Long-Acting Reversible Contraception: Implants and Intrauterine Devices. Number 121.
3. Lira-Plasenica, J, Bahamontes, L. (2014). Anticoncepción intrauterina en mujeres nulíparas como estrategia para disminuir los embarazos no planeados en América Latina. Ginecol Obstet México; 82:111-122. Volumen 82, Núm. 2. Pág: 111-122
4. Strasser, J, Borkowski, L, Couillard, M. (2016). Long-Acting Reversible Contraception. Jacobs Intitute of Women’s Health.
5. Hoopes, A, Simmons K. (2016) U.S Medical Eligibility Criteria for Contraceptive Use. Table K1.
6. DeCherney, A. (2013). Diagnóstico y tratamiento ginecoobstétricos. 11a edición, pág. 940-942, México DF. Mc Graw Hill.
7. R, Varma, D, Sinha. (2006). Non-contraceptive uses of levonorgestrel-releasing hormone system (LNG-IUS) a systematic enquiry and overview. European Journal of Obstetrics & Gynecology. Number: 125 (2006) 9-28.
2. The American College of Obstetrician and Gynecologist. (2011, reaffirmed 2015) Long-Acting Reversible Contraception: Implants and Intrauterine Devices. Number 121.
3. Lira-Plasenica, J, Bahamontes, L. (2014). Anticoncepción intrauterina en mujeres nulíparas como estrategia para disminuir los embarazos no planeados en América Latina. Ginecol Obstet México; 82:111-122. Volumen 82, Núm. 2. Pág: 111-122
4. Strasser, J, Borkowski, L, Couillard, M. (2016). Long-Acting Reversible Contraception. Jacobs Intitute of Women’s Health.
5. Hoopes, A, Simmons K. (2016) U.S Medical Eligibility Criteria for Contraceptive Use. Table K1.
6. DeCherney, A. (2013). Diagnóstico y tratamiento ginecoobstétricos. 11a edición, pág. 940-942, México DF. Mc Graw Hill.
7. R, Varma, D, Sinha. (2006). Non-contraceptive uses of levonorgestrel-releasing hormone system (LNG-IUS) a systematic enquiry and overview. European Journal of Obstetrics & Gynecology. Number: 125 (2006) 9-28.
Downloads
Download data is not yet available.